Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry

SYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that results from its proof-of-concept trial, entitled “A phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder (MDD) and cognitive impairment (CI)” have been published as a peer-reviewed article in the British Journal of Psychiatry, a leading international journal in behavioural and psychiatric medicine.